Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8072495 | 0.90 | POLB (0.41) | POLBAPEX1HPGDSCNR1MAPT | |
| SCHEMBL570284 | 0.81 | MEN1 (0.49) | POLBAPEX1HPGDSMAPTMEN1 | |
| SCHEMBL1580209 | 0.81 | CASP1 (0.42) | POLBAPEX1CNR1MAPTMEN1 | |
| SCHEMBL13475471 | 0.80 | GRN (0.50) | POLBAPEX1 | |
| SCHEMBL9411718 | 0.80 | CNR2 (0.39) | S1PR2CNR1MAPTMEN1KMT2A | |
| SCHEMBL13701663 | 0.79 | TAS1R3 (0.51) | POLBHPGDSMAPTRIPK1LMNA | |
| SCHEMBL6970356 | 0.78 | HPGD (0.47) | S1PR2MEN1KMT2AALDH1A1TSHR | |
| SCHEMBL23060397 | 0.77 | S1PR2 (0.50) | S1PR2MEN1KMT2ALMNABCHE | |
| SCHEMBL29197138 | 0.77 | POLB (0.42) | POLBAPEX1CNR1MAPTLMNA | |
| SCHEMBL20908956 | 0.75 | HPGD (0.42) | S1PR2CNR1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| US-20110092505-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2011-04-21 | — | — | US | disclosed |
| WO-2009150230-A1 | 2,4'-BIPYRIDINYL COMPOUNDS AS PROTEIN KINASE D INHIBITORS USEFUL FOR THE TREATMENT OF IA HEART FAILURE AND CANCER | NOVARTIS AG (CH) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092505-A1 | ORGANIC COMPOUNDS | SLCO2B1, SLCO1B1, SLCO1B3 | POLB 745/4885APEX1 2671/4885S1PR2 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.